Wasamba will perform at the Walk in the Park fundraiser.
Camera IconWasamba will perform at the Walk in the Park fundraiser. Credit: Supplied/Supplied

East Fremantle: golfer Peter Carbon defies Parkinson’s diagnosis

Jessica NicoFremantle Gazette

WITH a slew of golfing titles from the 1970s and 80s, Peter Carbon’s name is one many in the local sporting community will remember.

The East Fremantle resident and former state champion was in the prime of his life when he found out he had Parkinson’s, a diagnosis which led him to become one of the first people to receive deep brain stimulation during its early trial stages.

Now 68 and more than 30 years after his diagnosis, Mr Carbon still loves golf and continues to both play and help with the Royal Fremantle Gold Club’s junior program, while also trying to raise awareness of Parkinson’s.

PerthNow Digital Edition.
Your local paper, whenever you want it.

Get in front of tomorrow's news for FREE

Journalism for the curious Australian across politics, business, culture and opinion.

READ NOW

He, along with his son Damien and wife Erica, will join hundreds of others next month for Parkinson’s WA’s A Walk in the Park fundraiser.

“Each year we come to A Walk in the Park as a family to support Parkinson’s WA and this year is no exception,” Damien said.

Fremantle group Wasamba will also be on hand for the event, warming up the crowd before the walk and entertaining them as they return.

Wasamba chair Robbie Watkins said the event gave them a chance to show the “wonderful” people taking part in the fundraiser that they were appreciated and that their commitment to the cause was admirable.

“The atmosphere is amazing and the ability to add something extra to that with our music is very rewarding for all our members,” he said.

A Walk in the Park is at Perry Lakes Reserve on September 17.

Visit www.parkinsons wa.org.au for more information.

MORE: Man injured after hitting retaining wall during police pursuit

MORE: Greenwood College on fairytale run to debating grand final

MORE: New study prompts rethink on chemo-first lung cancer treatment